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Abstract
Objective: Cardioprotective properties of recombinant human Erythropoietin (rhEpo) have been shown in in vivo regional or ex vivo global
models of ischemia—reperfusion (I/R) injury. The aim of this study was to characterize the cardioprotective potential of rhEPO in an in vivo
experimental model of global I/R approximating the clinical cardiac surgical setting and to gain insights into the myocardial binding sites of rhEpo
and the mechanism involved in its cardioprotective effect. Methods: Hearts of donor Lewis rats were arrested with cold crystalloid cardioplegia
and after 45 min of cold global ischemia grafted heterotopically into the abdomen of recipient Lewis rats. Recipients were randomly assigned to
control non-treated or Epo-treated group receiving 5000 U/kg of rhEpo intravenously 20 min prior to reperfusion. At 5 time points 5—1440 min
after reperfusion, the recipients (n = 6—8 at each point) were sacrificed, blood and native and grafted hearts harvested for subsequent analysis.
Results: Treatment with rhEpo resulted in a significant reduction in myocardial I/R injury (plasma troponin T) in correlation with preservation of
the myocardial redox state (reduced glutathione). The extent of apoptosis (activity of caspase 3 and caspase 9, TUNEL test) in our model was very
modest and not significantly affected by rhEpo. Immunostaining of the heart tissue with anti-Epo antibodies showed an exclusive binding of rhEpo
to the coronary endothelium with no binding of rhEpo to cardiomyocytes. Administration of rhEpo resulted in a significant increase in nitric oxide
(NO) production assessed by plasma nitrite levels. Immunostaining of heart tissuewith anti-phospho-eNOS antibodies showed that after binding to
the coronary endothelium, rhEpo increased the phosphorylation and thus activation of endothelial nitric oxide synthase (eNOS) in coronary
vessels. There was no activation of eNOS in cardiomyocytes. Conclusions: Intravenous administration of rhEpo protects the heart against cold
global I/R. Apoptosis does not seem to play a major role in the process of tissue injury in this model. After binding to the coronary endothelium,
rhEpo enhances NO production by phosphorylation and thus activation of eNOS in coronary vessels. Our results suggest that cardioprotective
properties of rhEpo are at least partially mediated by NO released by the coronary endothelium.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Myocardial protection from ischemia and reperfusion (I/R)
injury remains of paramount importance in the setting of
global myocardial ischemia associated with open-heart
surgical procedures. There has been considerable progress§ Presented at the 22nd Annual Meeting of the European Association for
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doi:10.1016/j.ejcts.2008.12.049made to date in myocardial protection strategies including
the use of blood cardioplegia [1]. Nevertheless, a high risk
subset of patients continue to suffer perioperatively from
myocardial I/R injury as exhibited by prolonged contractile
dysfunction, low-output syndrome, arrhythmias, periopera-
tive myocardial infarction and cardiac failure leading to
prolonged intensive care [2]. Thus, there is a compelling
necessity to improve myocardial protection from I/R injury
during open-heart surgical procedures.
There is a large body of experimental work showing the
non-hematopoietic cytoprotective properties of recombi-
nant human Erythropoietin (rhEPO) in a variety of tissues
subjected to I/R [3], including the retina [4], brain [5], and
cardiovascular system [6]. However, primary targets and
down stream mechanisms of the cardioprotective effect
of rhEpo remain controversial. The aim of this study was toSurgery. Published by Elsevier B.V. All rights reserved.
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vivo model of cold global I/R injury and to gain insights into
the primary targets and down streammechanisms involved in
its cardioprotective effect.
2. Materials and methods
2.1. Animals
Male Lewis rats (Harlan, Holland) weighing 250—300 g
were used as donors and recipients. All animals received
humane care in compliance with the European Convention
on Animal Care. This study was approved by the local
institutional ethics committee. The animals were maintained
in standard housing conditions with dry diet and water
available ad libitum.
2.2. Heterotopic heart transplantation
Donor rats were anesthetized with an i.p. injection of
pentobarbital (50 mg/kg of body weight) followed by admin-
istration of 500 units of i.v. heparin. The heart was arrested
with 10 ml/kg of body weight of cold (4 8C) crystalloid card-
ioplegic solution and stored in the same cardioplegic solution
at 4 8C until implantation.
Recipient rats were anesthetized with an i.p. injection of
pentobarbital and the donor heart was transplanted hetero-
topically according to the technique of Ono and Lindsey [7].
The total duration of global ischemia was 45 min of which the
last 15 min were needed for anastomoses.
2.3. Experimental design
Recipient rats were randomized to control non-treated
or Epo-treated group receiving 5000 U/kg of rhEpo
intravenously 20 min prior to reperfusion. At 5 time points
(5, 30, 60, 360, and 1440 min) after reperfusion the
recipients (n = 6—8 at each point) were sacrificed. Blood,
native and grafted hearts were harvested for subsequent
analyses.
2.4. Myocardial injury and tissue stress markers
Myocardial injury was assayed bymonitoring of the plasma
levels of cardiac troponin T isoform (cTnT) using electro-
chemiluminescent immunoassay (Roche Diagnostics, Switzer-
land). Plasma levels of atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) were determined by enzy-
matic immunoassay (Peninsula Laboratories, USA).
2.5. Systemic inflammatory response
Interleukin-6 (IL-6) in blood plasma was assessed using Rat
IL-6 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN).
2.6. Measurement of tissue ion and water content
Tissue Na+ and water content were assessed after drying
and burning the tissue sampled in metal-free concentrated
HNO3 using flame photometry and gravimetry, respectively.2.7. Apoptosis markers and signaling
Caspase 3 and caspase 9 activities were determined in
tissue homogenate using colorimetric peptide-based assay
kits (R&D Systems). Lysates of rat endothelial cell line (RBE4)
treated overnight with 0.5 mM Staurosporine (Sigma—
Aldrich, St. Louis, MO) were used as a positive control of
apoptosis [8]. The downstream product of active caspase 3,
cleaved poly (ADP-ribose) polymerase (PARP) was detected
using immuno-blotting with the rat-specific (Asp214) rabbit
polyclonal antibody diluted 1:1000 (Cell Signaling). The
CardioTACS in situ apoptosis detection kit (R&D Systems) was
used to estimate the number of TUNEL-based apoptosis-
positive nuclei.
2.8. Red cell, plasma and tissue reduced (GSH)/oxidized
Glutathione (GSSG) measurement
Blood and plasma samples were deproteinized and GSH
and GSSG were detected using Ellman’s reagent as described
elsewhere [9]. Tissue samples used for determination of the
GSH/GSSH levels were homogenized in equal volumes of
solutions containing either 100 mM KCl and 10 mM MOPS-KOH
or 5% trichloroacetic acid (TCA) in distilled water. After
centrifugation supernatant was used for the GSH/GSSG
detection using the same protocol as for the blood/plasma
samples (see above).
2.9. Product of nitric oxide (NO) metabolism in plasma
Stable product of NO oxidation, i.e. plasma nitrite level,
was detected using chemiluminescence assay by means of
CLD-88 (EcoMedica, Switzerland). Plasma samples were
collected immediately after blood harvest and concomitant
centrifugation (4 min, 8000 g).
2.10. Epo-induced signaling
Binding of rhEpo was assessed in acetone-fixed cryosec-
tions of transplanted and native ventricular tissue using
antibodies against Epo (R&D Systems).
Rabbit polyclonal antibodies against phosphorylated (Ser
1177) endothelial nitric oxide synthase (eNOS) (Cell Signal-
ing, 1:100) were used for immunohistochemical determina-
tion of eNOS phosphorylated eNOS in acetone-fixed frozen
sections. Secondary FITC-conjugated antibodies were
applied and localization of the specific staining determined
using fluorescent microscopy (Zeiss AxioScope 2500).
2.11. K+ influx measurements in neonatal rat
cardiomyocytes
The procedure of cell isolation is described in detail
elsewhere [10]. Unidirectional K+ influx was measured using
radioactive tracer technique. The cells (400 000 cells per
Petri dish, 3 cm1) were pre-treated with 1 mM ouabain and/
or rhEpo (final activity 10 U/ml) in the presence or absence of
100 mM L-arginine for 30 min. Thereafter flux detection was
initiated by adding 86Rb as a tracer for K+ (final activity
0.5 mCi/ml). Fluxes were assessed over half an hour with
tracer accumulation detected 5, 10, 20, and 30 min after the
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Fig. 2. (A) Plasma levels of atrial natriuretic peptide ANP in non-treated
control animals (basal) and 5 min after the onset of reperfusion in non-treated
control animals (control) and rhEpo-treated animals (Epo). Data are means of
6—8 independent experiments  SEM. * indicates p < 0.05 compared to the
corresponding time point in non-treated control group. (B) Plasma levels of
brain natriuretic peptide BNP in non-treated control animals (basal) and 5 min
after the onset of reperfusion in non-treated control animals (control) and
rhEpo-treated animals (Epo). Data are means of 6—8 independent experi-
ments  SEM. * indicates p < 0.05 compared to the corresponding time point in
non-treated control group.tracer application. Over this time period the accumulation of
tracer was a linear function of the incubation time. Samples
(10 ml) of the incubation media were collected and the cells
were washed free from extracellular 86Rb with ice-cold
incubation medium and finally lysed in 0.1 M NaOH. Cell
lysate was then used for detection of the intracellular 86Rb
and protein assessment (Bio-Rad protein assay). Unidirec-
tional potassium influx was then calculated from the slope of
the 86Rb uptake curve over time and normalized per amount
of the 86Rb in the incubation medium and per protein. Active
K+ transport mediated by the Na/K ATPase was calculated as a
difference between K+ fluxes in the presence and in the
absence of ouabain. Ouabain-resistant flux component was
addressed to as passive K+ influx.
2.12. Statistical analysis
All data are based on at least six replicates for in vivo
experiments and at least five independent experiments when
using cultured cardiomyocytes. They are presented as
mean  SEM. The comparison between the experimental
groups was performed using ANOVA and two-tailed Student’s
t-test for unpaired samples with normality test and Bon-
ferroni correction when analyzing simple time points
(GraphPad Instat.V3.05). The optimal number of experi-
ments per time point and group was chosen in accordance
with our previous experience [11]. The level of statistical
significance was set at p < 0.05.
3. Results
3.1. rhEpo and I/R myocardial damage
Significant reduction of the cardiac TnT plasma levels in
the rhEpo-treated group indicated that intravenous applica-
tion of the rhEpo could efficiently reduce both early and late
reperfusion-induced myocardial injury (Fig. 1). In particular,
rhEpo abolished acute release of the atrial and brain nat-
riuretic factors into the circulation upon restoration of bloodFig. 1. Plasma troponin T levels. Data are means of 6—8 independent experi-
ments  SEM (n = 6—8). * indicates p < 0.05 compared to the corresponding
time point in non-treated control group.perfusion of the graft (Fig. 2). Systemic inflammatory
response assessed as an increase in plasma IL-6 level 6 h
after the onset of perfusion was not affected by rhEpo
treatment (235  72 pg/ml vs 291  67 pg/ml in control and
rhEpo-treated recipients, p > 0.05). Thus, cardioprotective
effect of Epo was not due to the suppression of the secondary
inflammatory response.
The time from the onset of reperfusion to the defibrilla-
tion of the grafted heart was shorter in rhEpo-treated than
non-treated group (47  2 s vs 66  4 s, respectively, n = 40,
p = 00012).
3.2. Mechanisms of I/R injury
Interaction of rhEpo with its receptor was shown to reduce
apoptosis in isolated cardiomyocytes [3]. We have evaluated
the degree of apoptosis in transplanted hearts of control and
rhEpo-treated animals as well as between the transplanted
and native hearts.
To do so we have assessed caspase 9 and caspase 3
activity in ventricular tissue homogenate. The resulting
activity was compared between native and transplanted
hearts in both control and Epo-treated animal groups and
related to the activity of caspases in cell culture where
apoptosis was triggered by Staurosporine treatment.
The basal activity of caspase 3 and caspase 9 in the native
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Staurosporine-treated vascular endothelial cells for cas-
pase 3 and 0.20% of the positive control for caspase 9).
Ischemia—reperfusion resulted in a very modest increase of
the activity of both caspases which was only statistically
significant between the native and the transplanted hearts
30 min after the onset of perfusion (data not shown). This
difference was insignificant when caspases’ activity in
transplanted hearts of Epo-treated group were compared to
the native heart levels. Activation of caspase 3 did not
cause detectible PARP cleavage in transplanted hearts at
any reperfusion time point. In addition, the number of
TUNEL-positive cells ranged between 0 and 4 cells/20
field and did not differ statistically between non-treated
and rhEpo-treated ischemic hearts. Taken together with the
data on cardiac TnT release into the circulation these data
suggest that most of the ischemia—reperfusion damage
represents oncosis rather than apoptosis.
3.3. Cellular ion and water content
Data on tissue water and sodium content shown in Fig. 3A
and B provide further confirmation for the preferential
oncotic acute reperfusion damage. Reperfusion is followed
by a transient increase in tissue sodium and water levels inFig. 3. Effect of I/R and rhEpo on the tissue water and Na+ content. (A) Water
content in ventricular tissue of native non-ischemic hearts of the non-treated
control group (native) and in ischemic reperfused hearts of non-treated
control group (control) and rhEpo-treated group (Epo) 5 min after the onset
of perfusion. (B) Tissue Na+ content in the same set of samples. Data are means
of 6—8 hearts  SEM. * indicates p < 0.05 compared to the value in native
hearts.transplanted hearts of control but not in rhEpo-treated
animals. Recovery of the tissue ion/water balance occurred
within 30 min of reperfusion in both control grafts and rhEpo-
treated grafts.Fig. 4. Reduced glutathione levels in ventricular tissue homogenates of native
non-treated (n.control) and native rhEpo-treated (n.Epo) hearts, erythrocytes
and plasma. (A) GSH pool of ventricular tissue. Values are means of 6—8
independent heart samples  SEM. Note that the values for native hearts differ
between the control and rhEpo-treated animals (denoted with #, p < 0.05). *
indicates p < 0.05 compared to the native control value. (B) and (C) GSH levels
in erythrocytes and plasma. Data are means of 6—8 experiments  SEM. #
indicates p < 0.05 compared to the levels in non-treated control animals of the
corresponding time point. * denotes p < 0.05 compared to the basal level in
non-treated animals.
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Fig. 6. Localization of the rhEpo binding (stained in red) and eNOS activation
(phosphorylated active form stained in green) in the grafts. rhEpo localization
in the ventricular tissue of the grafts 5 min after the onset of reperfusion (A)
and 30 min after the onset of perfusion (B). Localization of the phospho-eNOS
(antibodies against phosphor-Ser 1177) in the transplanted hearts 5 min (C)
and 30 min (D) after the onset of perfusion. (For interpretation of the
references to color in this figure legend, the reader is referred to the web
version of the article.)3.4. Reperfusion and oxidative stress
Oxidation is one of the recognized causes of the myo-
cardial damage at reperfusion. Indeed, reperfusion resulted
in acute depletion of the GSH pool in ventricular tissue that
became even more pronounced with time (Fig. 4A). Admin-
istration of rhEpo resulted in an increase in the GSH content
in native myocardium ( p < 0.05). Transplanted hearts of the
rhEpo-treated group did not show GSH depletion at any
reperfusion time point (Fig. 4A). Intravenous administration
of rhEpo also abolished reduction of the GSH levels in
erythrocytes and plasma of the recipient animals thus
providing systemic defense from the reperfusion-induced
oxidative stress (Fig. 4B and C).
3.5. Mechanisms of the cardioprotective action of rhEpo
As shown in Figs. 3 and 4, rhEpo protects transplanted
myocardium from reperfusion-induced oxidative stress,
edema and Na+ accumulation. Plasma nitrite levels in
recipient animals were significantly upregulated following
rhEpo administration indicating an increase in nitric oxide
production (Fig. 5). The source of NO production was
characterized by using antibodies against phosphorylated
(active) forms of endothelial nitric oxide synthase. Interest-
ingly, rhEpo treatment resulted in activation of eNOS
selectively in vascular endothelium of coronary vessels but
not in the myocardial tissue itself (Fig. 6C and D). Cardiac
myocytes are known to express eNOS along with vascular
endothelial cells. We therefore investigated localization of
rhEpo in both native and transplanted heart tissue. The data
presented in Fig. 6A and B indicate that rhEpo does not
diffuse from the lumen of the coronary vessels into the
myocardium at least for the first 30 min of reperfusion. Both
the rhEpo binding and activation of the eNOS are restricted to
the endothelial compartment.
In order to address the possible effect of rhEpo on ion and
water equilibrium in more details we have monitored the
active and passive K+ transport across the sarcolemmal
membrane of primary cultures of cardiac myocytes in theFig. 5. Nitrite levels in plasma of rhEpo-treated animals (rhEpo) and non-
treated control animals (control). Data are means of 6—8 animals  SEM. *
denotes p < 0.05 compared to the corresponding time point in non-treated
control animals.
Fig. 7. Total, passive and active K+ influx components into neonatal rat
cardiomyocytes in the presence or in the absence of 10 U/ml rhEpo in the
medium containing 100 mM L-arginine (A) or in arginine-free medium (B). Data
are means of five independent experiments  SEM. *** and * indicates
p < 0.001 and p < 0.05 correspondingly when compared to the Epo-free
conditions.
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rhEpo resulted in stimulation of the active influx of K+
mediated by the Na/K ATPase along with suppression of
passive K+ movement across the sarcolemma (Fig. 7A). This
does not occur when the cell incubation medium is deprived
of L-arginine, a substrate of eNOS (Fig. 7B) suggesting the
observed effects of rhEpo on both the Na/K ATPase and
the passive K+ flux are not direct but secondary to the Epo-
induced stimulation of NO production.
4. Discussion
Choosing an in vivo model of cold global ischemia and
warm reperfusion we intended to mimic as closely as possible
the clinical setting during open-heart surgical procedures.
The narrow time window of cardioprotection for rhEpomakes
it almost useless when treating myocardial infarction (first
hours after the injury) [3,12]. The preoperative period on the
contrary allows precisely timed administration of the drug
assuring maximal cardioprotective effect of rhEpo. To our
knowledge, the present study is the first one investigating the
myocardial action of rhEpo during cold global I/R injury in
vivo. Our data indicate that in i.v. administration of rhEpo
after the onset of cold global ischemia but prior to warm
reperfusion confers an acute cardioprotective effect in rats.
This cardioprotection offered by rhEpo was not linked to the
suppression of apoptosis but to the reduction of oxidative
stress and edema, which was at least partially mediated by
the rhEpo-induced stimulation of NO production.
This observation is in line with numerous reports of
cardioprotective efficiency of rhEpo obtained using different
models and experimental settings including isolated rat
cardiomyocytes [6,13—15], in vitro Langendorff model
[6,13,16—18] and in vivo coronary artery ligation model
[12,14,15,19]. Despite extensive investigations the mechan-
isms of rhEpo-induced cardioprotection remain a matter of
debate. Data generated using primarily isolated cardiomyo-
cytes, but also in some in vivo models suggest that rhEpo
protects myocardium from apoptosis [12,15]. However, the
role of apoptosis of cardiomyocytes in I/R injury is
questionable [1,20]. Our data reveal that, although occur-
ring, apoptosis does not contribute significantly to the cold
global I/R injury in our experimental model. Reperfusion
induced only marginal activation of caspase 9 and caspase 3
at only one time point (30 min of reperfusion). However, at
30 min of reperfusion rhEpo administration significantly
reduced myocardial cell injury reflected by plasma troponin
(Fig. 1). Of note, reduction inmechanical overload evidenced
by ANP and BNP release into the plasma was detectible even
earlier, already 5 min after the onset of blood flow (Fig. 2).
We were unable to monitor the changes in downstream
targets of caspase activation such as PARP cleavage or DNA
fragmentation suggesting that when occurring, apoptotic
response was incomplete. Very close to our results, van der
Meer and co-workers found only a modest proportion of
apoptotic cells positive for active caspase 3 in rat hearts
subjected to ischemia—reperfusion with (1.8  0.09%) or
without (2.1  0.12%) rhEpo treatment [18]. Interestingly,
activation of the caspase 3 in their study was mainly
restricted to the endothelial cells and fibroblasts. This findingis further supported by Scarabelli and co-workers reporting
that apoptosis of endothelial cells precedes cardiomyocyte
cell apoptosis in ischemia/reperfusion injury [20]. Parsa and
co-workers suggested a potential role of cardiac fibroblasts
in modulating cardioprotective effects of Epo in hearts
subjected to ischemia—reperfusion [14].
Edema and Na+ accumulation in the myocardial tissue we
have observed (Fig. 3) as well as delayed inflammatory
response are also not consistent with the concept of
apoptosis as a dominating course of I/R injury. Histological
examination revealed extensive myocardial lesions where
cell membranes lacked integrity, which became detectible
just 30 min after the onset of perfusion when cardiac TnTwas
detected in plasma of recipient animals (Fig. 1). Taken
together these findings suggest that most of the myocardial
damage represented oncotic necrosis.
Our data furthermore indicate that intravenous rhEpo
administration would fail to suppress apoptosis in the
myocardium even if the latter were occurring for one single
reason: rhEpo does not cross the endothelial barrier and
hence does not reach the myocardium at least during the first
hours of reperfusion (Fig. 6). Thus, data obtained for
interaction of the cytokine with isolated cardiomyocytes
[15] cannot be compared with those obtained using ex vivo or
in vivo models. The target for rhEpo applied intravenously is
primarily the endothelium of coronary vessels. Upon binding
to the endothelial cells occurring instantaneously (Fig. 6)
rhEpo causes activation of the NO production (Fig. 5) and
most likely other factors such as endothelin 1 [17] that are
mediating cardioprotective effects observed by us and
others.
Among the final targets of the rhEpo are reduction of
mechanical overload monitored as release of the stress
factors ANP and BNP, abrogation of the reperfusion-induced
oxidative stress (Fig. 4) and accelerated recovery of the ion
and water balance in the myocardial tissue (Fig. 3). It is
unlikely that the observed multiple effects are caused by
activation of a single signaling pathway. Detailed investiga-
tion of involved molecular events in potential signaling
pathways is far beyond the scope of this study. Similar
suppression of the ANP and BNP release upon reperfusion
following ischemia in rhEpo-treated animal models was
reported by others [17,19]. Antioxidative effect of rhEpo was
also shown in different tissues and experimental settings [3].
We suggest that activation of the NO production in the
endothelial cells is at least in part responsible for the lack of
GSH depletion in myocardial tissue during reperfusion. There
is long-standing debate as to whether NO plays a beneficial or
detrimental role in ischemia—reperfusion injury. It seems
tempting to extrapolate the results of in vitro experiments
using cell cultures to the in vivo pathogenic conditions [21].
Redox environment is the factor decisive for both NO
bioavailability and the end products formed which may
include both nitrite, nitrate, S- and N-nitrosylation adducts
and nitrotyrosine. It has been shown that lower levels of NO
production and diffusion into the tissue are associated with
its antioxidative properties [22]. The redox environment can
in turn modulate the NO function and potentiate its
cardioprotective action. This multifaceted action of NO
defines its narrow therapeutic safety window for NO in
ischemia—reperfusion pathophysiology [22]. In the present
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phosphorylation and activation of eNOS with subsequent
enhanced production of NO during the early phase of
reperfusion. Upregulation of NO production was associated
with reduction of oxidative stress and consequently of
myocardial injury. This is in accordance with previous report
of Bullard and co-workers who showed that the cardiopro-
tective effect of Epo was associated with a two-fold increase
in phosphorylated eNOS [13].
Along with its role as a scavenger of superoxide anions
NO has been shown to modulate numerous processes
including ion transport [23]. In our study, reduction in
myocardial injury was also accompanied by a decrease in
tissue edema and Na+ accumulation. We demonstrated that
activation of the NO production triggered by rhEpo
treatment of neonatal rat cardiomyocytes (our observa-
tions as well as [13,17,21]) modulated Na/K ATPase activity.
This is the first report on the role of NOS in regulation of the
active K+ transport in cardiomyocytes. However, our recent
study revealed similar coupling between NOS-mediated NO
production and activity of the Na/K ATPase in cerebellar
granule cells [23]. Along with activation of the Na/K ATPase
reduction of the passive K+ fluxes is observed in the
cardiomyocytes where NO generation is induced by rhEpo
furthermore facilitating restoration of the transmembrane
ion gradients (Fig. 7).
There are limitations in the present study related to its
design. Focusing mainly on investigating the mechanisms of
Epo-induced cardioprotection, we chose a fixed dose at a
fixed time of administration of rhEpo. However, the dose of
5000 U/kg rhEpo used in our study has been shown to confer
significant cardioprotection against ischemia—reperfusion
[12]. After demonstrating the cardioprotection conferred by
rhEpo, we limited our study to the potential role of NO
alone. We cannot exclude that other local or systemic
factors modulated by rhEpo such as endothelin 1, vascular
endothelial growth factor and transforming growth factor
may play a significant role in the acute and late cardiopro-
tection induced by rhEpo [3,17]. The involvement of other
secondary effectors in the cardioprotection offered by rhEpo
warrants further investigations. Moreover, our rodent model
does not allow to assess clinical relevance of the obtained
results but gives insight for further characterization of
mechanisms of potential cardioprotection offered by Epo in
human settings.
In summary, intravenous administration of rhEpo after the
onset of ischemia but prior to reperfusion protects the heart
against cold global I/R. Apoptosis does not seem to play a
major role in the process of tissue injury in this model. After
binding to the coronary endothelium, rhEpo enhances
NO production by phosphorylation and thus activation of
endothelial nitric oxide synthase in coronary vessels. Our
data suggest that cardioprotective properties of rhEpo are at
least partially mediated by nitric oxide released by the
coronary endothelium.
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Appendix A. Conference discussion
Dr T. Wahlers (Cologne, Germany): Yesterday in the Young Investigators
Award, the action of Epo on stem cells was reported and they used in rats a
dose of 3000 units/kg. You used 5000. Can you give us your rationale using this
high dose of Epo and transfer this perhaps to the human side.
Dr Tavakoli: I think one should make a difference between the cell culture
model or in vivo model. Besides, the aim of our study was just to prove the
cardioprotective potential of Epo and, as I mentioned, get insights into its
mechanism. We chose this dose and also the time of administration based on
previous studies, again, in an in vivo regional model where the authors have
shown that 5000 units/kg is efficient [ref. 19 in the manuscript]. I think in the
acute setting of this study the proliferative properties of Epo wouldn’t be a
major problem.
Dr J. Vaage (Oslo, Norway): I think you have a very interesting model by
transplanting the hearts back to the animals. I have two questions for you.
You showed that the erythropoietin binds to the endothelium, but you gave
it only very briefly before taking out the heart. I think it was 20 min.
Dr Tavakoli: Right.Dr Vaage: Do you have any data or any information that if you keep it, let’s
say, 6 h or 24 h, before you could find it located in other places like, for
instance, the cardiomyocytes. That’s my first question.
My second is more comment. You claim that the effect is partly mediated
by endothelial NO. I actually refute that, because you just showed that it is
upregulated, which is not in any way an indication that it is the mediator. In
order to show that you need either pharmacological blocking or using mice
with knockout NO.
Dr Tavakoli: First, your first question about the timing of the application,
as I mentioned, this was not a study to investigate the optimal timing of Epo
injection. The curve I’ve shown you indicates that the half-life of Epo is about
2 h. This information was obtained after we started the study, so we did not
change the timing and the doses of Epo administration.
Regarding your second input, you know that NO itself is an antioxidative
molecule, so this is the reason I suggest that NO is related to the antioxidative
and cardioprotective effect of Epo in this model. Therefore, it’s one
explanation for my assertion that NO is involved in this cardioprotection
and antioxidative action of Epo.
Dr Vaage: If I may comment on it. There is, let’s say, scientific background
for making that suggestion, but I think we must make it very clear at this stage
of your investigation it’s only a suggestion.
Dr Tavakoli: Correct. It’s a suggestion. To be able to say our data indicate
that NO is related, we should have put an inhibitor of eNOS and shown that it
could abolish the effect of EPO. Hence, it warrants further investigation. I
think the best way to say it indicates is that you block the effect of EPO with
inhibitors of eNOS.
